Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juraj Velcicky

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|October 24, 2008
Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activityAchim Schlapbach, Roland Feifel, Stuart Hawtin, et al.
Journal of Medicinal Chemistry|April 27, 2017
Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and AngiogenesisJuraj Velcicky, Wolfgang Miltz, Berndt Oberhauser, et al.
Bioorganic & Medicinal Chemistry|July 11, 2017
Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesisWolfgang Miltz, Juraj Velcicky, Janet Dawson, et al.
Bioorganic & Medicinal Chemistry Letters|July 2, 2010
In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part IILaszlo Revesz, Achim Schlapbach, Reiner Aichholz, et al.
Bioorganic & Medicinal Chemistry Letters|July 3, 2010
In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part ILaszlo Revesz, Achim Schlapbach, Reiner Aichholz, et al.
Journal of Medicinal Chemistry|January 24, 2018
Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In VivoJuraj Velcicky, Ursula Bodendorf, Pascal Rigollier, et al.
Journal of Medicinal Chemistry|August 29, 2020
Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral ExposureJuraj Velcicky, Rainer Wilcken, Simona Cotesta, et al.
ACS Medicinal Chemistry Letters|June 22, 2019
Discovery of Orally Active Hydroxyethylamine Based SPPL2a InhibitorsJuraj Velcicky, Casey J N Mathison, Victor Nikulin, et al.
Journal of Medicinal Chemistry|January 4, 2024
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 InhibitorsJuraj Velcicky, Philipp Janser, Nina Gommermann, et al.
Chemmedchem|May 20, 2026
A 24-Day MicroCycle Journey to Interleukin-17 Inhibitors: From Library Design to Central Core Prioritization and Capping Group IdentificationSophie Racine, Odile Decoret, Marco Palmieri, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|October 24, 2008
Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activityAchim Schlapbach, Roland Feifel, Stuart Hawtin, et al.
Journal of Medicinal Chemistry|April 27, 2017
Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and AngiogenesisJuraj Velcicky, Wolfgang Miltz, Berndt Oberhauser, et al.
Bioorganic & Medicinal Chemistry|July 11, 2017
Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesisWolfgang Miltz, Juraj Velcicky, Janet Dawson, et al.
Bioorganic & Medicinal Chemistry Letters|July 2, 2010
In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part IILaszlo Revesz, Achim Schlapbach, Reiner Aichholz, et al.
Bioorganic & Medicinal Chemistry Letters|July 3, 2010
In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part ILaszlo Revesz, Achim Schlapbach, Reiner Aichholz, et al.
Journal of Medicinal Chemistry|January 24, 2018
Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In VivoJuraj Velcicky, Ursula Bodendorf, Pascal Rigollier, et al.
Journal of Medicinal Chemistry|August 29, 2020
Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral ExposureJuraj Velcicky, Rainer Wilcken, Simona Cotesta, et al.
ACS Medicinal Chemistry Letters|June 22, 2019
Discovery of Orally Active Hydroxyethylamine Based SPPL2a InhibitorsJuraj Velcicky, Casey J N Mathison, Victor Nikulin, et al.
Journal of Medicinal Chemistry|January 4, 2024
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 InhibitorsJuraj Velcicky, Philipp Janser, Nina Gommermann, et al.
Chemmedchem|May 20, 2026
A 24-Day MicroCycle Journey to Interleukin-17 Inhibitors: From Library Design to Central Core Prioritization and Capping Group IdentificationSophie Racine, Odile Decoret, Marco Palmieri, et al.
Pageof 3